Clover Health Investments, Corp. CLOV
Set alert
4.22 USD -0.09 -2.09%
As of Nov 3, 11:29 AM ET
4.20 Day range 4.37
1.58 52-week range 5.59
- YTD
- +79.57%
- 1 year
- +14.67%
- Open
- 4.31
- Prev close
- 4.31
- Mkt cap
- 2.24B
- Vol
- 1.02M
- Avg vol
- 4.22M
- EPS
- -0.05
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.20
- High
- 4.37
- Forward P/E
- 28.73
- Beta
- 2.48
- Short ratio
- 5.73
- Inst. own
- 33.93%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 4.51
- 200-d avg
- 3.54
- 1y target
- 5.50
YTD chart
Events in this range
- Feb 26, 2026Earnings: -0.05; estimate -0.10212; surprise 51.04%
- Mar 20, 2026Rating: Canaccord Genuity · Buy → Buy
- May 6, 2026Earnings: 0.07; estimate 0.07; surprise 0%
- Jun 4, 2026Rating: Canaccord Genuity · Buy → Buy
- Jun 11, 2026Rating: UBS · Neutral → Neutral
- Jul 21, 2026Rating: Canaccord Genuity · Buy → Buy
- Aug 5, 2026Earnings: 0.05; estimate 0.03864; surprise 29.4%
- Aug 6, 2026Rating: UBS · Neutral → Neutral
- Oct 28, 2026Rating: Needham · — → Buy
Signals (40)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 20, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 19, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 19, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 4 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 25, 2026 | 1 month ago |
| RSI: Overbought | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 10, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 1, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| RSI: Overbought | Jul 1, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 30, 2026 | 4 months ago |
Newest 20 of 40.
Analyst view
Consensus: buy
Buy
Price target (mean) 5.50 +30.3% upside
Now 4.22
- Target (low)
- 5.00
- Target (mean)
- 5.50
- Target (high)
- 6.00
Ratings (0m) 5 3 buy · 2 hold · 0 sell
- Strong buy1
- Buy2
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 4
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.01 | 0.01 – 0.01 | 0.0033 | +203.0% | 738.42M | +48.7% | 1 |
| Next quarter | -0.02 | -0.02 – -0.02 | -0.0459 | +56.4% | 723.47M | +48.3% | 1 |
| Current year | 0.14 | 0.14 – 0.14 | 0.039 | +259.0% | 2.95B | +53.5% | 1 |
| Next year | 0.15 | 0.15 – 0.15 | 0.14 | +7.1% | 3.54B | +19.8% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Needham | Initiated | — | Buy |
| Aug 6, 2026 | UBS | Maintained | Neutral | Neutral |
| Jul 21, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 11, 2026 | UBS | Maintained | Neutral | Neutral |
| Jun 4, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 20, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 5, 2026 | Leerink Partners | Maintained | Market Perform | Market Perform |
| Jan 20, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 6, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 7, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 6, 2025 | UBS | Maintained | Neutral | Neutral |
| Mar 3, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Dec 17, 2024 | Craig-Hallum | Initiated | — | Buy |
| Oct 7, 2024 | UBS | Initiated | — | Neutral |
| Aug 11, 2023 | Citigroup | Maintained | Neutral | Neutral |
| Mar 6, 2023 | Canaccord Genuity | Maintained | — | Buy |
| Mar 6, 2023 | Credit Suisse | Maintained | — | Underperform |
| Nov 16, 2022 | Citigroup | Maintained | — | Neutral |
| Nov 8, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Aug 9, 2022 | Citigroup | Maintained | — | Neutral |
| Aug 9, 2022 | Credit Suisse | Maintained | — | Underperform |
| May 10, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Feb 25, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Feb 2, 2022 | Canaccord Genuity | Initiated | — | Buy |
| Feb 2, 2022 | Cowen & Co. | Upgrade | Underperform | Market Perform |
| Jan 19, 2022 | SVB Leerink | Initiated | — | Market Perform |
| Jan 7, 2022 | Credit Suisse | Downgrade | Neutral | Underperform |
| Nov 15, 2021 | Credit Suisse | Maintained | — | Neutral |
| Sep 10, 2021 | Cowen & Co. | Initiated | — | Underperform |
| Jul 12, 2021 | JP Morgan | Downgrade | Neutral | Underweight |